Original articleRanibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy
Abbreviations and Acronyms
Cited by (0)
See Editorial on page 985.
Supplemental material available at www.ophthalmologyretina.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): C.C.W.: Consultant — Alcon, Adverum Biotechnologies, Alimera, Alnylam, Allergan, Atheneum Partners, Bayer, Clearside, Consultants LLC, CORCEPT, Destum Partners, Inc, Dutch Ophthalmic Research Center, Genentech, Inc., Hexal AG, K2C Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, Regeneron, Santen, System Analytic, Thrombogenics, Valeant; Research support — Aerpio, Alcon, Aldeyra Therapeutics, Allegro, Allergan, Apellis Pharmaceuticals, Astellas Pharma, Aura Biosciences, Boehringer Ingelheim, Chiltern International, Clearside, Diabetic Retinopathy Clinical Research Network, Genentech, Inc, GlaxoSmithKline, Iconic Therapeutics, INC Research, Johns Hopkins University, Novartis, OHR Pharmaceutical, Ophthotech, Ora, Inc., pSivida, Regeneron/Bayer, Regenxbio, Inc, Roche, Santen, SciFluor Life Sciences, Taiwan Liposome Company, Tyrogenex, Inc; Speakers’ bureau — Allergan, Regeneron.
D.A.E.: Consultant — Alimera Sciences, Allergan, Genentech, Inc., Regeneron; Advisory board — Alimera, Allergan, Genentech, Inc; Speakers’ bureau — Allergan, Genentech, Inc, Notal Vision; Research support — Alcon, Alimera, Allergan, Clearside TOGA Trial, Genentech, Inc, Ophthotech; Equity owner — Boston Image Reading Center, Hemera Biopharmaceuticals, USRetina.
D.B.R.: Consultant — Alimera Sciences, Allergan, Genentech, Inc, Ohr Pharmaceuticals, Regeneron; Speakers’ bureau — Allergan; Equity owner — Forsight Lab, Ohr Pharmaceuticals.
L.H.: Employee — Genentech, Inc.
A.E.F.: Employee — Genentech, Inc.
Z.H.: Employee — Genentech, Inc.
Supported by Genentech, Inc, South San Francisco, California, a member of the Roche Group, which provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation. Third-party writing assistance was provided by Betsy C. Taylor, PhD, CMPP, of Envision Pharma Group and funded by Genentech, Inc.
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
HUMAN SUBJECTS: Human subjects were included in this study. The human ethics committees at the participating sites approved the study. All research adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Wykoff, Hill, Fung, Haskova
Analysis and interpretation: Wykoff, Eichenbaum, Roth, Hill, Fung, Haskova
Data collection: Wykoff, Roth, Hill, Haskova
Obtained funding: Haskova
Overall responsibility: Wykoff, Eichenbaum, Roth, Hill, Fung, Haskova